Growth factors of the bombesin/gastrin releasing peptide (BN/GRP) family play a critical
role in proliferation and progression of malignancies. Inhibitors targeting GRP signalling have been
developed and tested as anticancer compounds showing promising preclinical and early phase clinical
results. In this review, we will discuss the molecular signaling, expression and the functional role of
BN/GRP-GRPR in different cancer models and will focus on the available strategies to target
BN/GRP-GRPR in cancer treatment as well as in tumour diagnosis and follow up.
Keywords: Cancer, neuropeptide, signaling transduction, drug targets, clinical trial.
Rights & PermissionsPrintExport